Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,985 | -1,598 | -2,629 | -356 | 752 |
| Depreciation Amortization | 168 | 153 | 108 | 105 | 108 |
| Accounts receivable | 783 | 148 | 651 | 539 | 579 |
| Accounts payable and accrued liabilities | -1,384 | 204 | -381 | -120 | -1,181 |
| Other Working Capital | 12 | 115 | 118 | 833 | -862 |
| Other Operating Activity | 1,567 | -1,116 | 311 | -450 | 613 |
| Operating Cash Flow | $-1,838 | $-2,093 | $-1,822 | $552 | $9 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -37 | -227 | -149 | -54 | -3 |
| Purchase Of Investment | -9 | -493 | -321 | -512 | -516 |
| Sale Of Investment | 1,032 | 1,069 | 26 | N/A | 6 |
| Other Investing Activity | -41 | 69 | -1,350 | 115 | 22 |
| Investing Cash Flow | $945 | $418 | $-1,794 | $-451 | $-491 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -34 | -26 |
| Common Stock Issued | 267 | N/A | 5,750 | 150 | N/A |
| Other Financing Activity | 32 | 4 | 525 | -8 | -2 |
| Financing Cash Flow | $299 | $4 | $6,275 | $108 | $-28 |
| Exchange Rate Effect | 194 | 40 | -260 | -215 | -154 |
| Beginning Cash Position | 2,887 | 4,518 | 2,119 | 2,124 | 2,788 |
| End Cash Position | 2,486 | 2,887 | 4,518 | 2,119 | 2,124 |
| Net Cash Flow | $-401 | $-1,631 | $2,399 | $-5 | $-664 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,838 | -2,093 | -1,822 | 552 | 9 |
| Capital Expenditure | -37 | -227 | -149 | -54 | -3 |
| Free Cash Flow | -1,875 | -2,320 | -1,972 | 498 | 6 |